Remy Cointreau
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Remy Cointreau
Rémy Cointreau is the world’s third-largest distiller of cognac by volume, with a 13% global volume share in 2024, according to Euromonitor. Cognac represented 62% of Rémy's sales in fiscal 2025. The remainder of Rémy’s portfolio is made up of smaller brands, including Cointreau orange liqueur, Metaxa Greek spirit, Mount Gay rum, Bruichladdich single malt scotch, The Botanist gin, Hautes Glaces French whiskey, and Westland American whiskey. The company also distributes third-party brands. Rémy is controlled by the Andromede family, which owns 42% equity interest and consolidates the business in the Andromede Group. The Cointreau family owns a further 27%, and the rest of the equity is a free float.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Remy Cointreau stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Remy Cointreau by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Remy Cointreau is RCOP:xpar. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Remy Cointreau has its primary listing on Euronext Paris. You can trade Remy Cointreau with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Remy Cointreau is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Remy Cointreau as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Remy Cointreau.